The company said revenue for the fiscal 2026 Q2 quarter ended March 31 rose 3.8% year over year to $78.4 billion. GAAP diluted EPS was $8.40, and adjusted diluted EPS was $4.75 (versus $4.42 a year earlier).

1. 01

   The company said revenue for the fiscal 2026 Q2 quarter ended March 31 rose 3.8% year over year to $78.4 billion. GAAP diluted EPS was $8.40, and adjusted diluted EPS was $4.75 (versus $4.42 a year earlier).

2. 02

   The company said it recognized a $1.1 billion gain in Other income, net in February 2026 tied to the OneOncology acquisition, from remeasuring its existing equity method investment and extinguishing the put option liability. It said this gain was included in the $8.40 increase in GAAP diluted EPS.

3. 03

   Cencora said it raised its fiscal 2026 adjusted diluted EPS outlook to $17.65 to $17.90 from the prior range of $17.45 to $17.75. It expects full-year net interest expense of about $485M and adjusted free cash flow of about $3.0B.

4. 04

   Cencora reported that operating cash flow was an outflow of $(966,530) thousand for the 6 months ended March 31. It also paid $4,932,036 thousand for acquisitions, net of cash acquired. The company said it funded part of the OneOncology acquisition through the issuance of senior notes totaling $3.0 billion and term loans totaling $1.5 billion.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.